GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2007

Cepheid and bioMerieux Partner on Sepsis Test

  • Cepheid and bioMerieux will together develop and commercialize an innovative line of sepsis test products on the GeneXpert® platform.

    The product menu comprises both bacterial and fungal identification assays as well a series of genetic markers for antibiotic resistance. There is also the potential for hospital-acquired pneumonia applications. 

    Cepheid will be in charge of manufacturing, and bioMerieux will distribute the sepsis assays on an exclusive, worldwide basis.

    In addition, bioMerieux has granted Cepheid a nonexclusive, worldwide license under the Hiramatsu patents on methicillin-resistant staphylococcus aureus (MRSA) for all applications. Cepheid will continue to develop, manufacture, and market MRSA products.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?